Nilvebrant Lisbeth
Nilvebrant Pharma Consulting AB, Bromma, Sweden.
Pharmacol Toxicol. 2002 May;90(5):260-7. doi: 10.1034/j.1600-0773.2002.900506.x.
Tolterodine and its major active 5-hydroxymethyl metabolite (5-HM) are potent muscarinic receptor antagonists that show selectivity for the urinary bladder over salivary glands in vivo. This tissue selectivity cannot be attributed to muscarinic receptor subtype selectivity, since both compounds are non-selective with respect to the M1-M5 receptor subtypes. The aim of the present in vitro study was to determine the specificity of tolterodine and 5-HM for muscarinic receptors compared to other potential cellular targets. Carbachol-induced contractions of isolated guinea pig bladder were effectively inhibited by tolterodine (IC50 14 nM) and 5-HM (IC50 5.7 nM). Tolterodine and 5-HM were weak inhibitors of effects mediated by alpha-adrenergic receptors (rat portal vein), histamine receptors (guinea pig ileum) and calcium channels (guinea pig potassium-depolarised urinary bladder, spontaneously beating right atria and electrically-driven right papillary muscle). The IC50 values were in the microM range and the antimuscarinic potency of tolterodine was 27, 200 and 370-485 times higher, respectively, than its potency in blocking histamine receptors, alpha-adrenoceptors and calcium channels. The active metabolite, 5-HM, was >900 times less potent at these sites than at bladder muscarinic receptors. Radioligand binding data on 54 different receptors and binding sites showed that tolterodine and 5-HM bind with significant affinity only at muscarinic receptors. In conclusion, the results of the present study indicate that both tolterodine and 5-HM are specific muscarinic receptor antagonists. The tissue selectivity of these agents in vivo cannot therefore be explained by secondary pharmacological actions.
托特罗定及其主要活性5-羟甲基代谢物(5-HM)是强效毒蕈碱受体拮抗剂,在体内对膀胱的选择性高于唾液腺。这种组织选择性不能归因于毒蕈碱受体亚型选择性,因为这两种化合物对M1 - M5受体亚型均无选择性。本体外研究的目的是确定与其他潜在细胞靶点相比,托特罗定和5-HM对毒蕈碱受体的特异性。托特罗定(IC50 14 nM)和5-HM(IC50 5.7 nM)可有效抑制卡巴胆碱诱导的离体豚鼠膀胱收缩。托特罗定和5-HM对α-肾上腺素能受体(大鼠门静脉)、组胺受体(豚鼠回肠)和钙通道(豚鼠低钾去极化膀胱、自发性跳动的右心房和电驱动的右乳头肌)介导的效应是弱抑制剂。IC50值在微摩尔范围内,托特罗定的抗毒蕈碱效力分别比其阻断组胺受体、α-肾上腺素能受体和钙通道的效力高27、200和370 - 485倍。活性代谢物5-HM在这些位点的效力比在膀胱毒蕈碱受体处低900倍以上。关于54种不同受体和结合位点的放射性配体结合数据表明,托特罗定和5-HM仅以显著亲和力结合毒蕈碱受体。总之,本研究结果表明托特罗定和5-HM都是特异性毒蕈碱受体拮抗剂。因此,这些药物在体内的组织选择性不能用次要药理作用来解释。